02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
19:34 , Oct 19, 2018 |  BC Week In Review  |  Clinical News

BioLineRx reports response, survival data for BL-8040, Keytruda combo in pancreatic cancer

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) reported data from the Phase IIa COMBAT/KEYNOTE-202 trial showing that BL-8040 plus Keytruda pembrolizumab led to a disease control rate (DCR) of 34.5%, including one partial response and nine cases...
21:53 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

BioLineRx reports additional Phase IIa data for BL-8040 in AML

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) reported data from the expansion portion of a Phase IIa trial in 16 patients with relapsed or refractory acute myelogenous leukemia (AML) showing that BL-8040 as monotherapy for two days...
21:24 , Nov 10, 2017 |  BC Week In Review  |  Company News

iPharma gets rights to Boehringer's FAK inhibitor

Boehringer Ingelheim GmbH (Ingelheim, Germany) granted iPharma Ltd. exclusive, worldwide rights to develop and commercialize BI 853520, a focal adhesion kinase inhibitor. iPharma is a JV formed in August 2016 by BioLineRx Ltd. (Tel Aviv:BLRX;...
23:02 , Nov 3, 2017 |  BC Extra  |  Company News

iPharma gets rights to Boehringer's FAK inhibitor

Boehringer Ingelheim GmbH (Ingelheim, Germany) granted iPharma Ltd. exclusive, worldwide rights to develop and commercialize BI 853520, a focal adhesion kinase inhibitor. iPharma is a JV formed in August 2016 by BioLineRx Ltd. (Tel Aviv:BLRX;...
17:45 , Aug 10, 2017 |  BC Week In Review  |  Clinical News

Genentech starts Phase Ib/II evaluating immunotherapy-based combos for pancreatic ductal adenocarcinoma

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) began an open-label, international Phase Ib/II trial to evaluate multiple immunotherapy-based combinations with PD-L1 inhibitor Tecentriq atezolizumab (MPDL3280A, RG7446) compared to chemotherapy with gemcitabine plus Abraxane nab-paclitaxel...
23:20 , Apr 7, 2017 |  BioCentury  |  Finance

Taking notice

  Political overhang during the first quarter kept generalists on the sidelines but provided a buying opportunity for life sciences specialists that led the sector to outperform. With “repeal and replace” in the rearview for...
19:45 , Mar 31, 2017 |  BC Week In Review  |  Company News

Agalimmune, BioLineRx deal

BioLineRx acquired cancer company Agalimmune for $3 million in cash and $3 million in BioLineRx shares up front, plus undisclosed milestones. Agalimmune's lead compound AGI-134 is slated to begin clinical testing to treat solid tumors...
19:33 , Mar 31, 2017 |  BC Week In Review  |  Financial News

BioLineRx completes follow-on

Cancer and immunology company BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) raised $25 million through the sale of 29.4 million ADSs at $0.85 in a follow-on underwritten by JMP Securities, H.C. Wainwright and Maxim Group on March...
21:51 , Feb 9, 2017 |  BC Week In Review  |  Clinical News

BL-8040: Ph II started

BioLineRx said the University of Texas MD Anderson Cancer Center began an open-label, U.S. Phase II trial to evaluate subcutaneous 1.25 mg/kg BL-8040 plus 200 mg IV Keytruda pembrolizumab in about 15 patients. Patients will...